
Opinion|Videos|June 9, 2025
The MOA of TLX250
Panelists discuss how the new tracing agent (Zr-DFO-girentuximab or 2050) works by binding to carbonic anhydrase IX, an enzyme expressed on the surface of most clear cell renal cancers, coupled with zirconium for radiographic detection.
Advertisement
Episodes in this series

The Novel Tracer 89Zr-TLX250
Main Discussion Topics:
- 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX).
- CAIX is an enzyme expressed on the surface of most clear cell renal cell carcinomas (ccRCCs).
- The antibody is coupled to zirconium-89, a positron emitter detectable on PET imaging.
Key Points for Physicians:
- The tracer targets CAIX, which is highly expressed in ccRCC.
- The mechanism of action involves antibody binding coupled with a radioactive tracer.
- Zirconium-89 serves as the positron-emitting component for detection.
Notable Insights:
The targeting of CAIX represents a specific molecular approach to identifying ccRCC based on its unique expression pattern.
Clinical Significance:
This targeted molecular approach represents a fundamental shift from anatomic to biological characterization of renal masses.
Advertisement
Related to this article

Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
5


